HER2+ Breast Cancer | Specialty

Upfront Use of Second-Line Agents in ALK+ NSCLC

April 27th 2017

Treatment of Relapsed/Refractory ALK+ NSCLC

April 27th 2017

Repeat Mutation Testing at ALK-Rearranged NSCLC Progression

April 27th 2017

ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC

April 27th 2017

FDA Approval of Brigatinib for ALK+ NSCLC

April 27th 2017

Patterns of Progression on Crizotinib for ALK+ NSCLC

April 27th 2017

The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

April 27th 2017

Dr. Osborne on Pertuzumab in HER2+ Breast Cancer

April 25th 2017

Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Expert Weighs in on Future of HER2-Positive Breast Cancer Treatment

April 20th 2017

C. Kent Osborne, MD, sheds light on the current and future treatment of HER2-positive breast cancer.

Dr. Osborne Discusses Targeting the HER2 Pathway in Breast Cancer

April 18th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

FDA Schedules ODAC Meeting for Neratinib in HER2+ Breast Cancer

April 18th 2017

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 24, 2017, to discuss a new drug application for neratinib as a treatment for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab, according to a statement from the developer of the TKI, Puma Biotechnology.

Dr. Janni on Challenges Facing the Treatment of HER2-Positive Breast Cancer

April 18th 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses challenges facing the treatment options for patients HER2-positive breast cancer.

HER2-Enriched Subtype Predicts Response to Dual HER2 Blockade in Early Breast Cancer

April 10th 2017

According to results from the PAMELA trial, women with the HER2-enriched subtype of early-stage, HER2-positive breast cancer were more likely to have a pathological complete response when treated with dual HER2-blockade.

Novel HER2 Inhibitor May Help Treat Brain Tumors in Breast Cancer Patients

April 7th 2017

Investigators are seeking to determine whether adding tucatinib (ONT-380), a novel small-molecule HER2 inhibitor, to standard therapies will improve outcomes for patients with progressive metastatic HER2-positive breast cancer, including those with brain tumors.

Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer

April 5th 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

Dual HER2 Targeting Effective in Refractory mCRC Subset

April 2nd 2017

A dual attack on HER2 expression resulted in a 30% objective response rate in heavily pretreated patients with HER2-positive metastatic colorectal cancer.

Neratinib Shows Promise in HER2-Mutated Cancers

April 2nd 2017

The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with HER2-mutant advanced cancers.

Overcoming Resistance to HER2-Targeted Therapy in Breast Cancer

March 29th 2017

Mark D. Pegram, MD, discusses resistance mechanisms being studied in the quest to overcome resistance to HER2-targeted therapy in breast cancer.

Findings From the SystHERs Real-World Study of HER2+ Breast Cancer

March 27th 2017

Mohammad Jahanzeb, MD, discusses the SystHERs trial, which was designed to provide real-world insight into current treatment patterns, long-term survival, and patient experience with multiple different treatments for HER2-positive metastatic breast cancer.

Dr. Osborne on the Benefits of Dual-Targeted Therapy for HER2+ Breast Cancer

March 25th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefits of dual-targeted therapy for patients with HER2-positive breast cancer.